LAVA Therapeutics NV
LVTX evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Lead Asset:
- lava-1266 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for LVTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
lava-1266 (Phase 1)
Next Catalyst
—
Tracking 2 pipeline candidates · 2 clinical trials for LAVA Therapeutics NV.
Similar companies
Run LAVA Therapeutics NV through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LAVA Therapeutics NV facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is LAVA Therapeutics NV's lead drug candidate?
LAVA Therapeutics NV's most advanced tracked candidate is lava-1266 (Phase 1) for Metastatic Castration Resistant Prostate Cancer.
Who is the CEO of LAVA Therapeutics NV?
Stephen Hurly Stephen is the chief executive officer of LAVA Therapeutics NV (LVTX).
What therapeutic areas does LAVA Therapeutics NV focus on?
LAVA Therapeutics NV develops therapies across Oncology, Rare Disease, Immunology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.